Overall rank by patents
#36,312
Across all tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 14 technology areas, active 2015–2017. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C08L (COMPOSITIONS OF MACROMOLECULAR COMPOUNDS).
The verdict
M&g holds 7 US patents across 14 technology areas, rank #36,312 of 50,000 tracked assignees.
M&G USA Corporation has been granted 7 US utility patents between 2015 and 2017, placing M&G USA Corporation at rank #36,312 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.6 claims per patent with primary concentration in C08L (COMPOSITIONS OF MACROMOLECULAR COMPOUNDS). As a US Corporation, M&G USA Corporation is one of the more focused assignees in the PatentsView dataset. By volume, M&g sits between Lysosomal Therapeutics Inc. (7 patents, rank #36,308) and M.a.e. S.p.a. (7 patents, rank #36,316) - the closest US assignees by grant volume. The composite Innovation Score of 29.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 7 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. M&G USA Corporation's 15.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark M&G USA Corporation against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Lysosomal Therapeutics Inc.
7 patents
M & Q IP Leasing, LLC
7 patents
M Cubed Technologies, Inc.
7 patents
M et P Pharma AG
7 patents
M&M Oil Tools, LLC
7 patents
M-Edge International Corporation
7 patents
M-TEC CO., LTD.
7 patents
M.A.E. S.p.A.
7 patents
M&G USA Corporation
7 patents
What this shows M&G holds 7 patents at rank #36,312, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #36,312 in granted patent volume.
Other assignees with the most granted patents in M&G's primary technology class.
M&g's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 68% higher than 32% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 4 | 57.1% |
| 2016 | 1 | 14.3% |
| 2017 | 2 | 28.6% |
Top 14 of 14 technology areas
Overall rank by patents
#36,312
Across all tracked assignees
29.8 out of 100
How to use this portfolio
M&g's 7 grants land it in the top 68% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.